Seven of the eight SS-LCH patients were treated with surgery, and the remaining 19 MS-LCH patients were all initially treated with systemic chemotherapy, with 10 BRAF V600E positive patients receiving targeted therapy at a later stage. This evidence concerns the gene BRAF and myeloid sarcoma.